NovoCure Ltd (NVCR) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
NovoCure’s revenue went from $83M in fiscal 2016 to $655M in fiscal 2025, growth of about 25.8% a year.
Net income in fiscal 2025 was -$136M, a net margin of -20.8%; the best year in this period was 2020 with $20M.
Over the twelve months to September 30, 2026, revenue was $725M and net income -$122M.
Free cash flow was -$76M in fiscal 2025 and positive in 4 of the 10 years shown.
The diluted share count rose 30% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $725M | $655M | $605M | $509M | $538M | $535M | $494M | $351M | $248M | $177M | $83M |
| Gross profit | $559M | $488M | $468M | $381M | $423M | $420M | $388M | $263M | $168M | $121M | $37M |
| Operating income | -$125M | -$154M | -$170M | -$233M | -$90M | -$44M | $30M | -$914000 | -$34M | -$39M | -$115M |
| Net income | -$122M | -$136M | -$169M | -$207M | -$93M | -$58M | $20M | -$7M | -$64M | -$62M | -$132M |
| EPS (diluted) | $-1.06 | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.18 | $-0.07 | $-0.69 | $-0.70 | $-1.54 |
| R&D | $229M | $225M | $210M | $223M | $206M | $201M | $132M | $79M | $51M | $38M | $41M |
| Revenue growth | — | +8.3% | +18.8% | −5.3% | +0.5% | +8.2% | +40.7% | +41.6% | +40.1% | +113.6% | +150.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$722000 | -$49M | -$26M | -$73M | $31M | $83M | $99M | $27M | -$2M | -$33M | -$108M |
| Capital spending | -$24M | -$27M | -$43M | -$27M | -$21M | -$24M | -$15M | -$10M | -$7M | -$7M | -$6M |
| Free cash flow | -$25M | -$76M | -$69M | -$100M | $9M | $59M | $84M | $16M | -$9M | -$40M | -$113M |
| Dividends paid | — | — | — | — | — | — | — | — | — | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $117M | $105M | $160M | $116M | $107M | $95M | $76M | $52M | $40M | $27M | $22M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $448M | $960M | $911M | $969M | $938M | $843M | $326M | $246M | $183M | $220M |
| Debt | — | $248M | $683M | $604M | $590M | $582M | $451M | $168M | $149M | $97M | $96M |
| Equity | — | $340M | $360M | $362M | $441M | $410M | $477M | $218M | $112M | $114M | $142M |
| Total assets | — | $804M | $1.2B | $1.1B | $1.2B | $1.1B | $1.1B | $479M | $340M | $265M | $282M |
| Shares (diluted) | 117M | 111M | 108M | 106M | 105M | 103M | 109M | 97M | 92M | 89M | 86M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 77.0% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% | 74.8% | 67.7% | 68.6% | 44.2% |
| Operating margin | -17.2% | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% | 6.2% | -0.3% | -13.6% | -22.2% | -139.1% |
| Net margin | -16.8% | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% | -2.1% | -25.6% | -34.8% | -159.1% |
| FCF margin | -3.4% | -11.6% | -11.4% | -19.7% | 1.8% | 10.9% | 17.0% | 4.6% | -3.5% | -22.9% | -136.7% |
| ROIC | — | -26.1% | -12.9% | -19.0% | -6.9% | -3.5% | 2.6% | -0.2% | -10.2% | -14.7% | -38.2% |
| ROE | — | -40.0% | -46.8% | -57.1% | -21.0% | -14.2% | 4.2% | -3.3% | -56.6% | -54.3% | -92.6% |
Frequently asked questions
What is NovoCure’s annual revenue?
$655M in fiscal 2025 and $725M over the twelve months to September 30, 2026.
How much profit does NovoCure make?
Net income was -$136M in fiscal 2025 (net margin -20.8%).
Is NovoCure’s revenue growing?
Yes: revenue rose 8.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.